NeoGenomics, Inc. (NEO) |
|
9.69 0.58 (6.37%)
|
06-26 22:16 |
|
Open: |
9.16 |
Pre. Close: |
9.11 |
|
High:
|
9.76 |
Low:
|
8.93 |
|
Volume:
|
8,265,176 |
Market Cap:
|
1,209(M) |
|
|
|
|
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
9.77 - 9.81 |
9.81 - 9.85 |
|
Low:
|
8.84 - 8.88 |
8.88 - 8.92 |
|
Close:
|
9.62 - 9.69 |
9.69 - 9.77 |
|
Technical analysis |
as of: 2022-06-24 4:41:52 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 11.39  One year: 13.31 |
| Support: |
Support1: 7.96 Support2: 6.84 |
| Resistance: |
Resistance1: 9.76 Resistance2: 11.39 |
| Pivot: |
7.93 |
| Moving Average: |
MA(5): 8.34 MA(20): 8.05
MA(100): 13.28  MA(250): 29.36 |
| MACD: |
MACD(12,26): -0.2 Signal(9): -0.5 |
| Stochastic oscillator: |
%K(14,3): 83.4 %D(3): 61.7 |
| RSI: |
RSI(14): 61.4 |
| 52-week: |
High: 54.74 Low: 6.84 |
| Average Vol(K): |
3-Month: 2,403 (K) 10-Days: 2,611 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ NEO ] has closed above the upper band by 11.2%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 37.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Sun, 26 Jun 2022
The first neo-financial institution in KSA opts for ICS BANKS Digital Platform from ICSFS - ZAWYA
Sat, 25 Jun 2022
The 10 Best '80s Neo-Noir Movies, According To Reddit - Screen Rant
Sat, 25 Jun 2022
Martin Hinteregger retires at 29 after outrage over links to Austrian Neo-Nazi figure - Daily Mail
Fri, 24 Jun 2022
Samsung Neo G8 vs Samsung Neo G9 - TrustedReviews
Thu, 23 Jun 2022
AYA NEO AIR series debuts on Indiegogo from US$499 with AMD Barcelona APUs and OLED displays - Notebookcheck.net
Thu, 23 Jun 2022
How Russia Uses Neo-Nazi Groups to Spread Chaos - Voice of America - VOA News
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Diagnostics & Research |
| Shares Out. |
123 (M) |
| Shares Float |
120 (M) |
|
% Held by Insiders
|
2.5 (%) |
|
% Held by Institutions
|
91.6 (%) |
|
Shares Short
|
5,510 (K) |
|
Shares Short P.Month
|
5,220 (K) |
Stock Financials |
|
EPS
|
0.4 |
|
EPS Est Next Qtl
|
0.03 |
|
EPS Est This Year
|
0.12 |
|
EPS Est Next Year
|
0.23 |
|
Book Value (p.s.)
|
9.22 |
|
Profit Margin (%)
|
-7.4 |
|
Operating Margin (%)
|
-28.7 |
|
Return on Assets (ttm)
|
-5.3 |
|
Return on Equity (ttm)
|
-3.8 |
|
Qtrly Rev. Growth
|
1.3 |
|
Gross Profit (p.s.)
|
1.56 |
|
Sales Per Share
|
3.94 |
|
EBITDA (p.s.)
|
-0.69 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-58 (M) |
|
Levered Free Cash Flow
|
-66 (M) |
Stock Valuations |
|
PE Ratio
|
24.22 |
|
PEG Ratio
|
-7.7 |
|
Price to Book value
|
1.04 |
|
Price to Sales
|
2.45 |
|
Price to Cash Flow
|
-20.59 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
